

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Robert G. Pergolizzi et al.

Serial No. 08/479,995

Filed: June 7, 1995

Title: COMPOSITION UTILIZING
POLYNUCLEOTIDE SEQUENCES
TO DETECT AN ANALYTE

Group Art Unit: 1807

Examiner: Ardin Marschel, Ph.D.

527 Madison Avenue, 9th Floor
New York, New York 10022
February 20, 1997

FILED BY EXPRESS MAIL

Honorable Commissioner of Patents and Trademarks
United States Patent and Trademark Office
Washington, D.C. 20231

Box: Non-Fee Amendment



**SUPPLEMENTAL COMMUNICATION TO APPLICANTS'
APRIL 12, 1996 SECOND PRELIMINARY AMENDMENT
AND APRIL 15, 1996 SUPPLEMENTAL AMENDMENT THERETO**

Dear Sir:

This Supplemental Communication follows Applicants' April 12, 1996 Second Preliminary Amendment and April 15, 1996 Supplemental Amendment to Applicants' April 12, 1996 Second Preliminary Amendment. No extension fee is believed necessary because Applicants are awaiting a first action by the Examiner.

Claims 283 - 438 are currently pending in this application. Claims 283 - 437 were submitted in Applicants' April 12, 1996 Second Preliminary Amendment and claim 438 was submitted in their April 15, 1996 Supplemental Amendment.

Enz-11(C2)(D1)(C2)

EXPRESS MAIL CERTIFICATE	
"Express Mail" Label No.	EM449424142
Deposit Date	FEBRUARY 20, 1997
I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231	
 Ronald C. Fedus Re: Enz-11(C2)	 Date

Pergolizzi et al.

Serial No.: 08/479,995

Filing Date: June 7, 1995

Page 2 (Supplemental Communication To Applicants' April 12, 1996 Second Preliminary Amendment and April 15, 1996 Supplemental Amendment Thereto) - February 20, 1997)

In an effort to assist the Examiner's review of pending claims 283-438, Applicants' undersigned attorney has prepared and is submitting herewith a claim chart (attached hereto as Exhibit 1). The attached chart shows support for each of the previously submitted claims. It is believed that the accompanying chart is self-explanatory and should be helpful in allowing the Examiner to track the support for the subject matter of each claim. Applicants' Washington associates are hand delivering a courtesy copy to Dr. Ardin Marschel in Group 1807.

No fee is believed due in connection with this Supplemental Communication. In the event that any fee or fees are due, however, authorization is given to change the amount of any such fee or fee(s) to Deposit Account No. 05-1135, or to credit any overpayment thereto.

Applicants are also submitting herewith a Change of Correspondence Address Request indicating the new communication numbers for Applicants' attorney.

If it would be helpful in expediting prosecution of this application, the undersigned may be contacted at (212) 583-0100 during business hours.

Respectfully submitted,



Ronald C. Fedus
Registration No. 32,567
Attorney for Applicants

Enzo Diagnostics, Inc.
c/o Enzo Biochem, Inc.
527 Madison Avenue (9th Floor)
New York, New York 10022
Telephone: (212) 583-0100
Facsimile: (212) 583-0150

D:\Corel\Office7\WPWin7\ENZ.11\C2D1C2\supple amend.wpd

Enz-11(C2)(D1)(C2)